Probing the origins, diagnosis and treatment of amyloid diseases using antibodies

Biochimie

Volumn 86, Issue 9-10, 2004, Pages 589-600

  Dumoulin, Mireille ^a   Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amyloid diseases; Antibodies and antibody fragments; Diagnostic and therapeutic strategies; Protein aggregation; Protein misfolding

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ANTIBODY; MONOCLONAL ANTIBODY; REAGENT;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; GENETIC PROCEDURES; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MENINGOENCEPHALITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STRUCTURE; SIDE EFFECT; VACCINATION;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTIBODIES; HUMANS;

EID: 8844257296     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biochi.2004.09.012     Document Type: Article

References (118)

1. S.E. Radford, and C.M. Dobson From computer simulations to human disease: emerging themes in protein folding Cell. 97 1999 291 298
2. P. Tompa Intrinsically unstructured proteins Trends Biochem. Sci. 27 2002 527 533
3. R. Sitia, and I. Braakman Quality control in the endoplasmic reticulum protein factory Nature 426 2003 891 894
4. A.L. Goldberg Protein degradation and protection against misfolded or damaged proteins Nature 426 2003 895 899
5. C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
6. P.J. Thomas, B.H. Qu, and P.L. Pedersen Defective protein folding as a basis of human disease Trends Biochem. Sci. 20 1995 456 459
7. M. Stefani, and C.M. Dobson Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution J. Mol. Med. 81 2003 678 699
8. V.N. Uversky, and A.L. Fink Conformational constraints for amyloid fibrillation: the importance of being unfolded Biochim. Biophys. Acta 1698 2004 131 153
9. G. Merlini, and V. Bellotti Molecular mechanisms of amyloidosis New Engl. J. Med. 349 2003 583 596
10. V.W. DeLaGarza Pharmacologic treatment of Alzheimer's disease: an update Am. Fam. Phys. 68 2003 1365 1372
11. L.E. Hebert, P.A. Scherr, J.L. Bienias, D.A. Benett, and D.A. Evans Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 60 2003 1119 1122
12. J.I. Guijarro, M. Sunde, J.A. Jones, I.D. Campbell, and C.M. Dobson Amyloid fibril formation by an SH3 domain Proc. Natl. Acad. Sci. USA 95 1998 4224 4228
13. F. Chiti, P. Webster, N. Taddei, A. Clark, M. Stefani, and G. Ramponi Designing conditions for in vitro formation of amyloid protofilaments and fibrils Proc. Natl. Acad. Sci. USA 96 1999 3590 3594
14. S.V. Litvinovich, S.A. Brew, S. Aota, S.K. Akiyama, C. Haudenschild, and K.C. Ingham Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module J. Mol. Biol. 280 1998 245 258
15. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson, and M. Stefani Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 2002 507 511
16. C.M. Dobson The structural basis of protein folding and its links with human disease, Philos Trans. R. Soc. London B Biol. Sci. 356 2001 133 145
17. M. Sunde, and C. Blake The structure of amyloid fibrils by electron microscopy and X-ray diffraction Adv. Prot. Chem. 50 1997 123 159
18. D.R. Booth, M. Sunde, V. Bellotti, C.V. Robinson, W.L. Hutchinson, and P.E. Fraser Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis Nature 385 1997 787 793
19. W. Colon, and J.W. Kelly Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro Biochemistry 31 1992 8654 8660
20. J.W. Kelly The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways Curr. Opin. Struct. Biol. 8 1998 101 106
21. V.N. Uversky, J. Li, and A.L. Fink Evidence for a partially folded intermediate in alpha-synuclein fibril formation J. Biol. Chem. 276 2001 10737 10744
22. R. Kayed, J. Bernhagen, N. Greenfield, K. Sweimeh, H. Brunner, and W. Voelter Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro J. Mol. Biol. 287 1999 781 796
23. J.D. Harper, and P.T. Lansbury Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu. Rev. Biochem. 66 1997 385 407
24. J. Zurdo Polypeptide models to understand protein misfolding and amyloid formation. Applications to protein design and therapeutics Prot. Pept. Lett. 2004 (in press)
25. L.A. Morozova-Roche, J. Zurdo, A. Spencer, W. Noppe, V. Receveur, and D.B. Archer Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants J. Struct. Biol. 130 2000 339 351
26. M.R. Krebs, D.K. Wilkins, E.W. Chung, M.C. Pitkeathly, A.K. Chamberlain, and J. Zurdo Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the beta-domain J. Mol. Biol. 300 2000 541 549
27. D. Hamada, and C.M. Dobson A kinetic study of beta-lactoglobulin amyloid fibril formation promoted by urea Prot. Sci. 11 2002 2417 2426
28. M. Dumoulin, A.M. Last, A. Desmyter, K. Decanniere, D. Canet, G. Larsson, A. Spencer, D.B. Archer, J. Sasse, S. Muyldermans, L. Wyns, C. Redfield, A. Matagne, C.V. Robinson, and C.M. Dobson A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme Nature 424 2003 783 788
29. Y. Yonezawa, S. Tanaka, T. Kubota, K. Wakabayashi, K. Yutani, and S. Fujiwara An insight into the pathway of the amyloid fibril formation of hen egg white lysozyme obtained from a small-angle X-ray and neutron scattering study J. Mol. Biol. 323 2002 237 251
30. A.K. Chamberlain, C.E. MacPhee, J. Zurdo, L.A. Morozova-Roche, H.A. Hill, and C.M. Dobson Ultrastructural organization of amyloid fibrils by atomic force microscopy Biophys. J. 79 2000 3282 3293
31. N.M. Kad, S.L. Myers, D.P. Smith, D.A. Smith, S.E. Radford, and N.H. Thomson Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy J. Mol. Biol. 330 2003 785 7999
32. M. Bouchard, J. Zurdo, E.J. Nettleton, C.M. Dobson, and C.V. Robinson Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy Prot. Sci. 9 2000 1960 1967
33. L. Nielsen, S. Frokjaer, J.F. Carpenter, and J. Brange Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy J. Pharm. Sci. 90 2001 29 37
34. J.L. Jimenez, J.I. Guijarro, E. Orlova, J. Zurdo, C.M. Dobson, and M. Sunde Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing EMBO J. 18 1999 815 821
35. J.L. Jimenez, E.J. Nettleton, M. Bouchard, C.V. Robinson, C.M. Dobson, and H.R. Saibil The protofilament structure of insulin amyloid fibrils Proc. Natl. Acad. Sci. USA 99 2002 9196 9201
36. M. Hoshino, H. Katou, Y. Hagihara, K. Hasegawa, H. Naiki, and Y. Goto Mapping the core of the beta(2)-microglobulin amyloid fibril by H/D exchange Nat. Struct. Biol. 9 2002 332 336
37. I. Kheterpal, H.A. Lashuel, D.M. Hartley, T. Walz, P.T. Lansbury Jr., and R. Wetzel Abeta protofibrils possess a stable core structure resistant to hydrogen exchange Biochemistry 42 2003 14092 14098
38. I. Kheterpal, S. Zhou, K.D. Cook, and R. Wetzel Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange Proc. Natl. Acad. Sci. USA 97 2000 13597 13601
39. A. Olofsson, J.H. Ippel, S.S. Wijmenga, E. Lundgren, and A. Ohman Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy J. Biol. Chem. 279 2004 5699 5707
40. P.T. Lansbury Jr., P.R. Costa, J.M. Griffiths, E.J. Simon, M. Auger, and K.J. Halverson Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide Nat. Struct. Biol. 2 1995 990 998
41. A.T. Petkova, G. Buntkowsky, F. Dyda, R.D. Leapman, W.M. Yau, and R. Tycko Solid state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide J. Mol. Biol. 335 2004 247 260
42. P. Polverino de Laureto, N. Taddei, E. Frare, C. Capanni, S. Costantini, J. Zurdo, F. Chiti, C.M. Dobson, and A. Fontana Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis J. Mol. Biol. 334 2003 129 141
43. M. Monti, B.L. Garolla di Bard, G. Calloni, F. Chiti, A. Amoresano, G. Ramponi, and P. Pucci The regions of the sequence most exposed to the solvent within the amyloidogenic state of a protein initiate the aggregation process J. Mol. Biol. 336 2004 253 262
44. F. Chiti, N. Taddei, M. Bucciantini, P. White, G. Ramponi, and C.M. Dobson Mutational analysis of the propensity for amyloid formation by a globular protein EMBO J. 19 2000 1441 1449
45. T. Chiba, Y. Hagihara, T. Higurashi, K. Hasegawa, H. Naiki, and Y. Goto Amyloid fibril formation in the context of full-length protein: effects of proline mutations on the amyloid fibril formation of beta2-microglobulin J. Biol. Chem. 278 2003 47016 47024
46. A.D. Williams, E. Portelius, I. Kheterpal, J.T. Guo, K.D. Cook, Y. Xu, and R. Wetzel Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis J. Mol. Biol. 335 2004 833 842
47. Sc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants Proc. Natl. Acad. Sci. USA 101 2004 10254 10259
48. + antiporter NhaA from Escherichia coli Biochim. Biophys. Acta 1610 2003 46 50
49. R. Loris, I. Marianovsky, J. Lah, T. Laeremans, H. Engelberg-Kulka, G. Glaser, S. Muyldermans, and L. Wyns Crystal structure of the intrinsically flexible addiction antidote MazE J. Biol. Chem. 278 2003 28252 28257
50. C. Ostermeier, S. Iwata, B. Ludwig, and H. Michel Fv fragment-mediated crystallization of the membrane protein bacterial cytochrome c oxidase Nat. Struct. Biol. 2 1995 842 846
51. G. Goldsteins, H. Persson, K. Andersson, A. Olofsson, I. Dacklin, and A. Edvinsson Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants Proc. Natl. Acad. Sci. USA 96 1999 3108 3113
52. V. Curin Serbec, M. Bresjanac, M. Popovic, K. Pretnar Hartman, V. Galvani, R. Rupreht, M. Cernilec, T. Vranac, I. Hafner, and R. Jerala Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob's disease-affected and normal brain tissue J. Biol. Chem. 279 2004 3694 3698
53. E. Paramithiotis, M. Pinard, T. Lawton, S. LaBoissiere, V.L. Leathers, W.Q. Zou, L.A. Estey, J. Lamontagne, M.T. Lehto, L.H. Kondejewski, G.P. Francoeur, M. Papadopoulos, A. Haghighat, S.J. Spatz, M. Head, R. Will, J. Ironside, K. O'Rourke, Q. Tonelli, H.C. Ledebur, A. Chakrabartty, and N.R. Cashman A prion protein epitope selective for the pathologically misfolded conformation Nat. Med. 9 2003 893 899
54. R.A. Williamson, D. Peretz, C. Pinilla, H. Ball, R.B. Bastidas, and R. Rozenshteyn Mapping the prion protein using recombinant antibodies J. Virol. 72 1998 9413 9418
55. D. Peretz, R.A. Williamson, Y. Matsunaga, H. Serban, C. Pinilla, and R.B. Bastidas A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform J. Mol. Biol. 273 1997 614 622
56. Y. Matsunaga, D. Peretz, A. Williamson, D. Burton, I. Mehlhorn, D. Groth, F.E. Cohen, S.B. Prusiner, and M.A. Baldwin Cryptic epitopes in N-terminally truncated prion protein are exposed in the full-length molecule: dependence of conformation on pH Proteins 44 2001 110 118
57. Sc conformational change J. Mol. Biol. 293 1999 855 863
58. C on the cell surface as probed by antibodies J. Mol. Biol. 326 2003 475 483
59. D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan, and D.J. Selkoe Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition Biochem. Soc. Trans. 30 2002 552 557
60. W.L. Klein Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets Neurochem. Int. 41 2002 345 352
61. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
62. P. Mangione, M. Sunde, S. Giorgetti, M. Stoppini, G. Esposito, L. Gianelli, L. Obici, L. Asti, A. Andreola, P. Viglino, G. Merlini, and V. Bellotti Amyloid fibrils derived from the apoliprotein A1 Leu74Ser variant contain elements of ordered helical structure Prot. Sci. 10 2001 187 199
63. C.P. Jaroniec, C.E. MacPhee, V.S. Bajaj, M.T. McMahon, C.M. Dobson, and R.G. Griffin High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy Proc. Natl. Acad. Sci. USA 101 2004 711 716
64. B. Solomon, R. Koppel, E. Hanan, and T. Katzav Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide Proc. Natl. Acad. Sci. USA 93 1996 452 455
65. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon Disaggregation of Alzheimer beta-amyloid by site-directed mAb Proc. Natl. Acad. Sci. USA 94 1997 4109 4112
66. D. Frenkel, O. Katz, and B. Solomon Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration Proc. Natl. Acad. Sci. USA 97 2000 11455 11459
67. J. McLaurin, R. Cecal, M.E. Kierstead, X. Tian, A.L. Phinney, M. Manea, J.E. French, M.H. Lambermon, A.A. Darabie, M.E. Brown, C. Janus, M.A. Chishti, P. Horne, D. Westaway, P.E. Fraser, H.T. Mount, M. Przybylski, and P. St George-Hyslop Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis Nat. Med. 8 2002 1263 1269
68. A.T. Petkova, Y. Ishii, J.J. Balbach, O.N. Antzutkin, R.D. Leapman, F. Delaglio, and R. Tycko A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR Proc. Natl. Acad. Sci. USA 99 2002 16742 16747
69. S. Emadi, R. Liu, B. Yuan, P. Schulz, C. McAllister, Y. Lyubchenko, A. Messer, and M.R. Sierks Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments Biochemistry 43 2004 2871 2878
70. B. O'Nuallain, and R. Wetzel Conformational Abs recognizing a generic amyloid fibril epitope Proc. Natl. Acad. Sci. USA 99 2002 1485 1490
71. R. Hrncic, J. Wall, D.A. Wolfenbarger, C.L. Murphy, M. Schell, and D.T. Weiss Antibody-mediated resolution of light chain-associated amyloid deposits Am. J. Pathol. 157 2000 1239 1246
72. D. Thompson, M.B. Pepys, I. Tickle, and S. Wood The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose J. Mol. Biol. 320 2002 1081 1086
73. M. Przybylski, V. Schnaible, J. Kast, S. Bohler, J. Michels, and A. Wattenberg Approaches to the characterisation of tertiary and supramolecular protein structures by combination of protein chemistry and mass spectrometry W. Ens New Methods for the Study of Biomolecular Complexes 1998 Kluwer Academic Publishers Amsterdam 17 43
74. E. Hanan, O. Goren, M. Eshkenazy, and B. Solomon Immunomodulation of the human prion peptide 106-126 aggregation Biochem. Biophys. Res. Commun. 280 2001 115 120
75. C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 1999 329 332
76. D. Peretz, R.A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, G. Schmitt-Ulms, I.R. Mehlhorn, G. Legname, M.R. Wormald, P.M. Rudd, R.A. Dwek, D.R. Burton, and S.B. Prusiner Antibodies inhibit prion propagation and clear cell cultures of prion infectivity Nature 412 2001 739 743
77. M.P. Lambert, K.L. Viola, B.A. Chromy, L. Chang, T.E. Morgan, J. Yu, D.L. Venton, G.A. Krafft, C.E. Finch, and W.L. Klein Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies J. Neurochem. 79 2001 595 605
78. Y. Gong, L. Chang, K.L. Viola, P.N. Lacor, M.P. Lambert, C.E. Finch, G.A. Krafft, and W.L. Klein Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss Proc. Natl. Acad. Sci. USA 100 2003 10417 10422
79. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, and J. Hardy A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985
80. J.C. Dodart, K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat. Neurosci. 5 2002 452 457
81. E. Kubler, B. Oesch, and A.J. Raeber Diagnosis of prion diseases Br. Med. Bull. 66 2003 267 279
82. A.F. Hill, M. Zeidler, J. Ironside, and J. Collinge Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy Lancet 349 1997 99 100
83. Sc detection in the preclinical diagnosis of scrapie Vet. Rec. 142 1998 564 568
84. D.A. Hilton, E. Fathers, P. Edwards, J.W. Ironside, and J. Zajicek Prion immunureactivity in appendix before clinical onset of variant Creutzfeldt-Jacob disease Lancet 352 1998 703 704
85. R.B. DeMattos, K.R. Bales, D.J. Cummins, S.M. Paul, and D.M. Holtzman Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 295 2002 2264 2267
86. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
87. F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, K. Khan, D. Kholodenko, C. Lee, M. Lee, R. Motter, M. Nguyen, A. Reed, D. Schenk, P. Tang, N. Vasquez, P. Seubert, and T. Yednock Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology Proc. Natl. Acad. Sci. USA 100 2003 2023 2028
88. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
89. C. Janus, J. Pearson, J. McLaurin, P.M. Mathews, Y. Jiang, and S.D. Schmidt A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982
90. D.M. Wilcock, A. Rojiani, A. Rosenthal, G. Levkowitz, S. Subbarao, J. Alamed, D. Wilson, N. Wilson, M.J. Freeman, M.N. Gordon, and D. Morgan Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition J. Neurosci. 24 2004 6144 6151
91. F.L. Heppner, C. Musahl, I. Arrighi, M.A. Klein, T. Rulicke, B. Oesch, R.M. Zinkernagel, U. Kalinke, and A. Aguzzi Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies Science 294 2001 178 182
92. E.M. Sigurdsson, D.R. Brown, M. Daniels, R.J. Kascsak, R. Kascsak, R. Carp, H.C. Meeker, B. Frangione, and T. Wisniewski Immunization delays the onset of prion disease in mice Am. J. Pathol. 161 2002 13 17
93. A.R. White, P. Enever, M. Tayebi, R. Mushens, J. Linehan, S. Brandner, D. Anstee, J. Collinge, and S. Hawke Monoclonal antibodies inhibit prion replication and delay the development of prion disease Nature 422 2003 80 83
94. D. Schenk Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning Nat. Rev. Neurosci. 3 2002 824 828
95. J.C. Dodart, K.R. Bales, and S.M. Paul Immunotherapy for Alzheimer's disease: will vaccination work? Trends Mol. Med. 9 2003 85 87
96. R.C. Dodel, H. Hampel, and H. Du Immunotherapy for Alzheimer's disease Lancet Neurol. 2 2003 215 220
97. E.M. Sigurdsson, T. Wisniewski, and B. Frangione A safer vaccine for Alzheimer's disease? Neurobiol. Aging 23 2002 1001 1008
98. A.R. White, and S.H. Hawke Immunotherapy as a therapeutic treatment for neurodegenerative disorders J. Neurochem. 87 2003 801 808
99. D.S. Gelinas, K. DaSilva, D. Fenili, P. St. George Hyslop, and J. McLaurin Immunotherapy for Alzheimer's disease Proc. Natl. Acad. Sci. USA 101 Suppl. 2 2004 14657 14662
100. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, E. Garcia, M.A. Wollmer, D. Umbricht, D.J. de Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos, and R.M. Nitsch Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554
101. E. Check Nerve inflamation halts trial for Alzheimer's drug Nature 415 2002 462
102. L. Solforosi, J.R. Criado, D.B. McGavern, S. Wirz, M. Sanchez-Alvarez, S. Sugama, L.A. DeGiorgio, B.T. Volpe, E. Wiseman, E. Masliah, D. Gilden, M.B. Oldstone, B. Conti, and R.A. Williamson Cross-linking cellular prion protein triggers neuronal apoptosis in vivo Science 303 2004 1514 1516
103. M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, P.M. Mathews, and M. Jucker Cerebral hemorrhage after passive anti-Abeta immunotherapy Science 298 2002 1379
104. S.M. Greenberg, B.J. Bacskai, and B.T. Hyman Alzheimer diseases double-edged vaccine Nat. Med. 9 2003 389 390
105. A. Monsonego, and H.L. Weiner Immunotherapeutic approaches to Alzheimer's disease Science 302 2003 834 838
106. C. Monnet, D. Laune, J. Laroche-Traineau, M. Biard-Piechaczyk, L. Briant, and C. Bes Synthetic peptides derived from the variable regions of an anti-CD4 monoclonal antibody bind to CD4 and inhibit HIV-1 promoter activation in virus-infected cells J. Biol. Chem. 274 1999 3789 3796
107. P. Amstutz, P. Forrer, C. Zahnd, and A. Pluckthun In vitro display technologies: novel developments and applications Curr. Opin. Biotechnol. 12 2001 400 405
108. D. Degl'Innocenti, N. Taddei, M. Ramazzotti, M. Stefani, F. Chiti, and G. Ramponi Selection of antibody fragments specific for an alpha-helix region of acylphosphatase J. Mol. Recognit. 17 2004 62 66
109. B. Bose, D.A. Chugh, M. Kala, S.K. Acharya, N. Khanna, and S. Sinha Characterization and molecular modeling of a highly stable anti-Hepatitis B surface antigen scFv Mol. Immunol. 40 2003 617 631
110. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, and E.B. Songa Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
111. S. Muyldermans Single domain camel antibodies: current status J. Biotechnol. 74 2001 277 302
112. M. Dumoulin, K. Conrath, A. Van Meirhaeghe, F. Meersman, K. Heremans, L.G. Frenken, S. Muyldermans, L. Wyns, and A. Matagne Single-domain antibody fragments with high conformational stability Prot. Sci. 11 2002 500 515
113. A. Muruganandam, J. Tanha, S. Narang, and D. Stanimirovic Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium FASEB J. 16 2002 240 242
114. M.B. Pepys, P.N. Hawkins, D.R. Booth, D.M. Vigushin, G.A. Tennent, and A.K. Soutar Human lysozyme gene mutations cause hereditary systemic amyloidosis Nature 362 1993 553 557
115. S. Valleix, S. Drunat, J.B. Philit, D. Adoue, J.C. Piette, D. Droz, B. MacGregor, D. Canet, M. Delpech, and G. Grateau Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family Kidney Int. 61 2002 907 912
116. M. Yazaki, S.A. Farrell, and M.D. Benson A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis Kidney Int. 63 2003 1652 1657
117. D. Canet, A.M. Last, P. Tito, M. Sunde, A. Spencer, D.B. Archer, C. Redfield, C.V. Robinson, and C.M. Dobson Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme Nat. Struct. Biol. 9 2002 308 315
118. A.K. Chamberlain, V. Receveur, A. Spencer, C. Redfield, and C.M. Dobson Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy Prot. Sci. 10 2001 2525 2530